Skeletal effects of sodium fluoride during hypokinesia.
This study tested the capacity of fluoride (F) to prevent the disuse-associated reduction in bone formation/growth. Suspending young male Wistar rats by the tail for 2-2.5 weeks reduced femoral cortical (P less than 0.05) and trabecular (P less than 0.01) bone areas. Tetracycline labelling showed that the decrement in cortical area was largely due to a reduction in the percent periosteal mineralizing surface (PsMS). Periosteal mineral apposition rate (PsMAR) was not affected. Endosteal mineralizing surface (EsMS) and mineral apposition rate (EsMAR) were significantly stimulated spontaneously during the second week of suspension. F treatment (5 mg/kg/day i.p.) prevented the loss in bone area, and established a trend toward increased PsMS without affecting EsMS and EsMAR. None of these changes are associated with alterations in serum Ca, P or osteocalcin. F treatment in hypokinetic animals caused a decrease in serum PTH (-21% compared to control; P = 0.001). We conclude that F prevents the development of hypokinetic osteopenia in rats.
Kidder
L S
LS
Department of Anthropology, Washington University, St. Louis, MO.
Klein
G L
GL
Stuart
C A
CA
Lee
T C
TC
Gundberg
C M
CM
Alcock
N
N
Cooper
C W
CW
Simmons
D J
DJ
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000517:prevention & control; D001862:Bone Resorption / Q000503:physiopathology; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects*; D007698:Kinesis; D008297:Male; D015675:Osteocalcin / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains; D012969:Sodium Fluoride / Q000494:pharmacology*; D014893:Weightlessness / Q000009:adverse effects*
D015675:Osteocalcin; D012969:Sodium Fluoride